Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:56 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects

NCT00449709
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Ejaculation
Interventions
GSK221149
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Nov 1, 2026, 4:56 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms

NCT02641912
View directory record Official record
Conditions
Xerostomia
Interventions
Biotene mouthwash, Mineral Water
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Nov 1, 2026, 4:56 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2409021 Formulations in Healthy Participants

NCT02385084
View directory record Official record
Conditions
Healthy
Interventions
LY2409021
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults

NCT06216132
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
BIOPIN-6 Active Implant with Naltrexone, BIOPIN-6 Placebo Implant
Combination Product · Device
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

NCT07709741
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Formulation A, Formulation B, Formulation C
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

NCT02114229
View directory record Official record
Conditions
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions
alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
9
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

NCT01686217
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Food Effect, Healthy Volunteers
Interventions
ASP015K ER, ASP015K IR
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

NCT02609139
View directory record Official record
Conditions
Healthy
Interventions
PF-06650833
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

NCT03199339
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBA-7371, Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2940680 in Healthy Participants

NCT01681186
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Nov 1, 2026, 4:56 AM EST
Recruiting Phase 2 Interventional

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445
View directory record Official record
Conditions
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
Drug · Other
Lead sponsor
ONL Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

NCT03695237
View directory record Official record
Conditions
Central Precocious Puberty (CPP)
Interventions
Leuprolide Acetate (LA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Nov 1, 2026, 4:56 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

NCT06887010
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-101
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Nov 1, 2026, 4:56 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Interventions
Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

NCT01844323
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Formulation Reference, Palbociclib Formulation Test
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 4 Interventional

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

NCT00246610
View directory record Official record
Conditions
HIV Infection
Interventions
Nelfinavir mesylate, 625 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Nov 1, 2026, 4:56 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

NCT05322590
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 2 Interventional Results available

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

NCT00920218
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Nov 1, 2026, 4:56 AM EST
Completed Phase 1 Interventional

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

NCT03731715
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Nov 1, 2026, 4:56 AM EST
Active, not recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

NCT07246590
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102, Vehicle
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Miami, Florida • Saint Augustine, Florida • Meridian, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 4:56 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
23
States / cities
Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 1, 2026, 4:56 AM EST